Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

The Outcome of Three Weeks Rehabilitation in Patients With a Total Hip or Knee Replacement Experiencing Persistent Physical Impairments

NCT07105657 · tracked via the Priya Life Science Denmark tracker
Sponsor
Horsens Hospital
Phase
Observational
Started
2025-08-25
Last updated
2025-08-26

Condition(s) studied

Hip OsteoarthritisKnee Osteoarthristis

Investigational drug(s) / intervention(s)

Rehabilitation

Rehabilitation: Three weeks intensive rehabilitation where patients undergo group-based and individualised rehabilitation focusing at improving pain, function and quality of life for the patient

Study summary

Patients with total hip or knee replacement experiencing persistant problems are offered 3 weeks of intensive rehabilitation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- Patients with a total hip or knee replacement admitted for intensive rehabilitation Exclusion Criteria: * Patients unable to understand Danish * Unable to participate in physical tests * Unable to understand questionaires * Unable to participate i 6 months follow up

Primary outcome measure(s)

  • HOOS/KOOS pain (0-100 score) — Change from baseline (0) to 3 weeks
    Hip or knee related pain
  • HOOS/KOOS ADL (0-100 score) — Change from baseline (0) to 3 weeks
    Hip or knee related activities of daily living
  • HOOS/KOOS quality of life (0-100 score) — Change from baseline (0) to 3 weeks
    Hip or knee related quality of life
  • HOOS/KOOS pain (0-100 score) — Change from 3 weeks to 7 months
    Hip or knee related pain
  • HOOS/KOOS ADL (0-100 score) — Change from 3 weeks to 7 months
    Hip or knee related activities of daily living
  • HOOS/KOOS quality of life (0-100 score) — Change from 3 weeks to 7 months
    Hip or knee related quality of life
  • Sit-to-stand test — Change from baseline (0) to 3 weeks
    Number of completed sit to stands in 30 seconds
  • Sit-to-stand test — Change from 3 weeks to 7 months
    Number of completed sit to stands in 30 seconds

Trial sites (1)

FacilityCityRegionStatus
Horsens Regional Hospital Brædstrup Denmark Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07105657 on ClinicalTrials.gov ↗ ← All trials in Denmark